DoW Melanoma Research Program Focused Program Award – Rare Melanomas
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The FY26 Melanoma Research Program Focused Program Award – Rare Melanomas is designed to support multidisciplinary research initiatives consisting of two to three distinct but related projects centered on rare melanomas. The program emphasizes collaborative efforts led by an Initiating Principal Investigator and one to two Partnering Principal Investigators, each responsible for a specific research project. A key update for FY26 requires that at least one rare melanoma survivor or patient advocate be included on the research team to provide ongoing guidance and help ensure the research is impactful and patient-centered. Clinical trials are permitted within the proposed research scope. Submission involves a pre-application by the Initiating PI, followed by full application invitations for all named PIs, with the Partnering PIs submitting abbreviated proposals aligned with their projects. The Department of the Army, through the Congressionally Directed Medical Research Programs, plans to allocate approximately $5.6 million to fund about two awards under this opportunity, with each award capped at $2.8 million in total costs over a maximum performance period of four years. Funding for awards will come from FY26 allocations, with a final award date expected by September 30, 2027, and funds expiring by September 30, 2032. The program aims to advance focused research efforts on rare melanomas by fostering collaborative, patient-informed scientific inquiry with a strong translational potential.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Focused Program Award – Rare Melanomas, supports a multidisciplinary research program of at least two, but not more than three, distinct but complementary research projects addressing an overarching question relevant to rare melanomas.
Distinctive Features:
· *Updated for FY26* Investigators must include at least one rare melanoma survivor or patient advocate as part of the project team who will provide advice and consultation throughout planning, implementation, and results dissemination to maximize research impact.
· This is a partnering mechanism, requiring an Initiating Principal Investigator (PI) and at least one, but not more than two, Partnering PIs, see Figure 1.
○ Each named PI is expected to be a Project Leader for one of the proposed research projects. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).
· After submitting the required pre-application, investigators must receive an invitation to submit a full application.
○ Only the Initiating PI will submit a pre-application. All PIs must submit full applications. The Partnering PI(s)’s application is an abbreviated package specific to their proposed research project.
· Clinical trials are allowed.
Funding Details: The Congressionally Directed Medical Research Programs expects to allot roughly $5.6M to fund approximately 2 Focused Program Award – Rare Melanomas applications with total cost caps of $2.8M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
